Entrepreneurial Biotech Company Wows Audience
Entrepreneurial Biotech Company Wows International Audience
A2 Corporation received strong international interest in the commercialisation of A2 milk, as a result of the IDF World Dairy Summit held in Auckland last week.
A2 Corporation Chief Executive Dr Corran McLachlan says the interest in partnering the company's commercialisation initiatives and research programmes was overwhelming.
"We held one-on-one presentations with key international dairy companies and the interest is such that these discussions will continue post Summit," says Dr McLachlan. "This is an excellent result from our presence at a three day Summit."
Dairy companies spoken with include some of the major players from Europe, USA and Australia including Arla, Valio, Parmalat, Land O'Lakes, Bonlac and National Foods.
With around 800 delegates, the Summit provided a unique opportunity for the innovative Kiwi company to reach an international audience in a cost-effective manner.
Interest from the Summit delegates was three-fold: firstly, commercialisation of A2 milk and secondly, to further the research required to validate findings to date. A2 Corporation's mock packaging also received praise from delegates and packaging companies such as Amcor and Tetra Pak.
A2 Corporation is currently funding research carried out by the Wesley Institute in Brisbane, the Howard Florey Institute in Melbourne, the Barbara Davis Diabetes Institute in Denver Colorado and the Baker Medical Research Institute in Melbourne.
A2 Corporation is leading the world in research into the health effects of the beta casein proteins A1 and A2 present in cow's milk. There is evidence supporting a link between beta casein A1 and Type 1 (child) diabetes and beta casein A1 and coronary heart disease. Studies also show populations consuming pure A2 milk have extremely low rates of both Type 1 (child) diabetes and coronary heart disease.
A2 Corporation aims to make A2 milk available to New Zealand families in the first quarter of 2002.
A2 Corporation is one of a number of new bio-technology ventures being commercialised by South Island entrepreneur Howard Paterson.
For more information please contact: Sarah Williams, NBPR, phone 09 913 1830 or 021 928 125